Suboxone® (buprenorphine/naloxone) as an agonist opioid treatment in Spain: A budgetary impact analysis

European Addiction Research

Volumn 16, Issue 1, 2010, Pages 31-42

  Martínez Raga, José ^a   González Saiz, Francisco ^b   Pascual, César ^c   Casado, Miguel A ^d   Sabater Torres, Francisco J ^e  

^a Universidad Cardenal Herrera CEU   (Venezuela)

^b Fundacion Publica para la Atencion a las Drogodependencias e Incorporacion Social FADAIS   (Spain)

^c HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^d Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

^e Schering Plough   (Spain)

Author keywords

Budgetary impact analysis; Buprenorphine naloxone; Maintenance treatment; Methadone; Opiate dependence

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; METHADONE; BUPRENORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT;

ARTICLE; BUDGET; COST BENEFIT ANALYSIS; DATA BASE; DRUG COST; ECONOMIC EVALUATION; EXPERT SYSTEM; HEALTH CARE COST; OPIATE ADDICTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SPAIN; COMPARATIVE STUDY; ECONOMICS; HUMAN; METHODOLOGY;

ANALGESICS, OPIOID; BUDGETS; BUPRENORPHINE; HUMANS; NALOXONE; OPIOID-RELATED DISORDERS; SPAIN;

EID: 70449641177     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000259614     Document Type: Article

References (66)

1. Hser YI, Huang D, Chou CP, Anglin MD: Trajectories of heroin addiction: growth mixture modeling results based on a 33-year follow-up study. Eval Rev 2007; 31: 548-563.
2. United Nations Office for Drug Control and Crime Prevention (UNODCCP), 2002. Global Illicit Drug Trends. New York, United Nations Publications, 2002.
3. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Annual Report 2007. The state of the drugs problem in Europe. Luxembourg, Office for Official Publications of the European Communities, 2007.
4. Gowing LR, Farrell M, Ali RL, White JM: Alpha- 2-adrenergic agonists in opioid withdrawal. Addiction 2002; 97: 49-58.
5. Kosten TR, O'Connor PG: Management of drug and alcohol withdrawal. N Engl J Med 2003; 348: 1786-1795.
6. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP: An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005; 28: 321-329.
7. Vocci FJ, Acri J, Elkashef A: Medication development for addictive disorders: the state of the science. Am J Psychiatry 2005; 162: 1432-1440.
8. De la Fuente L, Brugal MT, Domingo-Salvany A, Bravo MJ, Neira-León M, Barrio G: More than thirty years of illicit drugs in Spain: a bitter story with some messages for the future. Rev Esp Salud Publica 2006; 80: 505-520.
9. Rosenheck R, Kosten T: Buprenorphine for opiate addiction: potential economic impact. Drug Alcohol Depend 2001; 63: 253-262.
10. Tober G, Strang J: Methadone Matters: Evolving Practice of Community Methadone Treatment of Opiate Addiction. New York, Taylor & Francis, 2003.
11. Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O'Connor PG, Schottenfeld RS: Counseling plus buprenorphine- naloxone maintenance therapy for opioid dependence. N Engl J Med 2006; 355: 365-374.
12. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D, for the Buprenorphine/Naloxone Collaborative Study Group: Office-based treatment of opiate addiction with a sublingual- tablet formulation of buprenorphinenaloxone. N Engl J Med 2003; 349: 949-958.
13. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE: A placebo-controlled trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995; 40: 17-25.
14. Kakko J, Svanborg KD, Kreek MJ, Heilig M: One-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden; a randomised, placebo-controlled trial. Lancet 2003; 361: 662-668.
15. Mattick RP, Breen C, Kimber J, Davoli M: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence Cochrane Database Syst Rev 2003;2:CD002209.
16. Mattick RP, Kimber J, Breen C, Davoli M: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2004;3:CD002207.
17. Amass L, Kamien JB, Mikulich SK: Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend 2000; 58: 143-152.
18. Schottenfeld RS, Pakes J, O'Connor P, Chawarski M, Oliveto A, Kosten TR: Thriceweekly versus daily buprenorphine maintenance. Biol Psychiatry 2000; 47: 1072-1079.
19. Davids E, Gastpar M: Buprenorphine in the treatment of opioid dependence. Eur Neuropsychopharmacol 2004; 14: 209-216.
20. European Medicines Agency (EMEA) European Public Assessment Report 2006. Suboxone H-C-697. http://wwwemeaeuropaeu/ humandocs/Humans/EPAR/suboxone/ suboxonehtm (accessed 3 April 2008).
21. Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S: Treating opioid addiction with buprenorphinenaloxone in community-based primary care settings. Ann Fam Med 2007; 5: 146-150.
22. Preston KL, Bigelow GE, Liebson IA: Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend 1990; 25: 27-34.
23. Stoller KB, Bigelow GE, Walsh SL, Strain EC: Effects of buprenorphine/naloxone in opioid- dependent humans. Psychopharmacology 2001; 154: 230-242.
24. Brosa M, Gisbert R, Rodríguez JM, Soto J: Principles, methods and applications of budgetary impact analysis in the health sector. Pharmacoeconomics - Spanish Research Articles 2005; 2: 65-79.
25. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins D, Nuijten M, Orlewska E, Trueman P, Watkins J: Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices - Budget Impact Analysis. Value Health 2006; 10 (available in http://www. ispor.org/workpaper/budget-impactasp).
26. Orlewska E, Mierzejewski P: Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health 2004; 7: 1-10.
27. Trueman P, Drummond M, Hutton J: Developing guidance for budget impact analysis. Pharmacoeconomics 2001; 19: 855-867.
28. Sullivan MA, Garawi F, Bisaga A, Comer SD, Carpenter K, Raby WN, Anen SJ, Brooks AC, Jiang H, Akerele E, Nunes EV: Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend 2007; 91: 289-292.
29. Kirchmayer U, Davoli M, Verster AD, Amato L, Ferri A, Perucci CA: A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction 2002; 97: 1241-1249.
30. Soto J, Sacristán JA, Galende I: Naturalistic studies to evaluate the effectiveness of medications following their commercialization: Why? When? How? Aten Primaria 1998; 22: 182-185.
31. De Wet CJ, Reed LJ, Bearn J: The rise of buprenorphine prescribing in England: analysis of NHS regional data, 2001-2003. Addiction 2005; 100: 495-499.
32. Sullivan LE, Chawarski M, O'Connor PG, Schottenfeld RS, Fiellin DA: The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend 2005; 79: 113-116.
33. Auriacombe M, Tignol J, Picard G: Buprenorphine use in France: quality of life and conditions for treatment success. Res Clin Forums 1997; 19: 25-32.
34. Alvarez FJ, Gonzalez-Saiz F: Buprenorphine prescription and the increased relative cost. Addiction 2005; 100: 1373-1374.
35. Lamont P, Hunt SC: A twist on torsade: a prolonged QT interval on methadone. J Gen Intern Med 2006; 21:C9-C12.
36. Routhier DD, Katz KD, Brooks DE: QTc prolongation and torsades de pointes associated with methadone therapy. J Emerg Med 2007; 32: 275-278.
37. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS: Torsade de pointes associated with very-highdose methadone. Ann Intern Med 2002; 137: 501-504.
38. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS: Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003; 23: 802-805.
39. Sanchez Hernandez AM, Atienza Fernandez F, Arenal Maiz A, Gonzalez Torrecilla E, Puchol Calderon A, Almendral Garrote J: Torsades de pointes during methadone treatment. Rev Esp Cardiol 2005; 58: 1230-1232.
40. Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, Piguet V, Musset T, Gaspoz JM, Perrier A, Dayer P, Desmeules JA: Druginduced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 2006; 166: 1280-1287.
41. Fanoe S, Hvidt C, Ege P, Jensen GB: Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart 2007; 93: 1051-1055.
42. Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A: QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res 2005; 11: 44-49.
43. Peles E, Bodner G, Kreek MJ, Rados V, Adelson M: Corrected QT intervals as related to methadone dose and serum level in methadone maintenance treatment patients: a cross-sectional study. Addiction 2007; 102: 289-300.
44. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC: QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007; 167: 2469-2475.
45. Krantz MJ, Garcia JA, Mehler PS: Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. Pharmacotherapy 2005; 25: 611-614.
46. Haasen C, Prinzleve M, Zurhold H, Rehm J, Güttinger F, Fischer G, Jagsch R, Olsson B, Ekendahl M, Verster A, Camposeragna A, Pezous AM, Gossop M, Manning V, Cox G, Ryder N, Gerevich J, Bácskai E, Casas M, Matali JL, Krausz M: Cocaine use in Europe - a multi-centre study methodology and prevalence estimates. Eur Addict Res 2004; 10: 139-146. (Pubitemid 40069604)
47. Peles E, Kreek MJ, Kellogg S, Adelson M: High methadone dose significantly reduces cocaine use in methadone maintenance treatment patients. J Addict Dis 2006; 25: 43-50.
48. Schwartz RP, Highfield DA, Jaffe JH, Brady JV, Butler CB, Rouse CO, Callaman JM, O'Grady KE, Battjes RJ: A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry 2006; 63: 102-109.
49. Moolchan ET, Umbricht A, Epstein D: Therapeutic drug monitoring in methadone maintenance: choosing a matrix. J Addict Dis 2001; 20: 55-73.
50. Quinn DI, Wodak A, Day RO: Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. Clin Pharmacokinet 1997; 33: 344-400.
51. Tennant F, Shannon J: Cocaine abuse in methadone maintenance patients is associated with low serum methadone concentrations. J Addict Dis 1995; 14: 67-74.
52. Mello NK, Mendelson JH, Bree MP, Lukas SE: Buprenorphine suppresses cocaine selfadministration by rhesus monkeys. Science 1989; 245: 859-862.
53. Mello NK, Negus SS: The effects of buprenorphine on self-administration of cocaine and heroin 'speedball' combinations and heroin alone by rhesus monkeys. J Pharmacol Exp Ther 1998; 285: 444-456.
54. Mello NK, Mendelson JH: Buprenorphine treatment of cocaine and heroin abuse; in Cowan A, Lewis JW (eds): Buprenorphine: Combating Drug Abuse with a Unique Opioid. New York, Wiley, 1995, pp 241-287.
55. Rodefer JS, Mattox AJ, Thompson SS, Carroll ME: Effects of buprenorphine and an alternative nondrug reinforcer, alone and in combination on smoked cocaine self-administration in monkeys. Drug Alcohol Depend 1997; 45: 21-29.
56. Mello NK, Lukas SE, Kamien JB, Mendelson JH, Drieze J, Cone EJ: The effects of chronic buprenorphine treatment on cocaine and food self-administration by rhesus monkeys. J Pharmacol Exp Ther 1992; 260: 1185-1193.
57. Foltin RW, Fischman MW: Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans. J Pharmacol Exp Ther 1996; 278: 1153-1164.
58. Kosten TR, Kleber HD, Morgan C: Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci 1989; 44: 887-892.
59. Kosten TR, Kleber HD, Morgan C: Treatment of cocaine abuse with buprenorphine. Biol Psychiatry 1989; 26: 637-639.
60. Oliveto AH, Kosten TR, Schottenfeld RS, Ziedonis D, Falcioni J: Cocaine use in buprenorphine- vs. methadone-maintained patients. Am J Addict 1994; 4: 43-48.
61. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR: Buprenorphine vs. methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997; 54: 713-720.
62. Schottenfeld RS, Chawarski MC, Pakes JR, Pantalon MV, Carroll KM, Kosten TR: Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry 2005; 162: 340-349.
63. Strain EC, Stitzer ML, Liebson IA, Bigelow GE: Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology 1994; 116: 401-406.
64. Gastfriend DR, Wapler M, Teoh SK Reif JH, Mendelson JH, Mello NK: Effects of buprenorphine on needle sharing, drug use and drug craving in men with combined heroin and cocaine dependence; in Harris LS (ed): Problems of Drug Dependence. 1992 NIDA Res Monogr 132. Washington, US Government Printing Office, 1993, p 312. (Pubitemid 23301846)
65. Schottenfeld RS, Pakes J, Ziedonis D, Kosten TR: Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol Psychiatry 1993; 34: 66-74.
66. Montoya ID, Gorelick DA, Preston KL, Schroeder JR, Umbricht A, Cheskin LJ, Lange WR, Contoreggi C, Johnson RE, Fudala PJ: Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther 2004; 75: 34-48.